Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2- advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial. Breast. 2022 Sep 28;66:77-84. doi: 10.1016/j.breast.2022.09.006. Epub ahead of print. PMID: 36206609; PMCID: PMC9535465. F.I.4,38 Q2

Inicio Repositorio Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2- advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial. Breast. 2022 Sep 28;66:77-84. doi: 10.1016/j.breast.2022.09.006. Epub ahead of print. PMID: 36206609; PMCID: PMC9535465. F.I.4,38 Q2

2022/09

Autores/as:

Salvador Bofill J, Moreno Anton F, Rodriguez Sanchez CA, Galve Calvo E, Hernando Melia C, Ciruelos Gil EM, Vidal M, Jiménez-Rodriguez B, De la Cruz Merino L, Martínez Jañez N, Villanueva Vazquez R, de Toro Salas R, Anton Torres A, Alvarez Lopez IM, Gavila

Servicio:

Oncología

Tipo:

Artículo

Materia:

https://pubmed.ncbi.nlm.nih.gov/36206609/

info@areasaludbadajoz.com

Contacto

Salud

Información

Ciudadanos

info@areasaludbadajoz.com

Contacto

Salud​

Información​

Ciudadanos​

Salud

Información

Ciudadanos